Reduction of the serotonin 5-HT1B and 5-HT2A receptor-mediated contraction of human pulmonary artery by the combined 5-HT1B receptor antagonist and serotonin transporter inhibitor LY393558.
CONCLUSIONS: LY393558 reduces the 5-HT-induced contraction antagonizing 5-HT1B and 5-HT2A receptors probably due to synergic interaction between SERT inhibition and 5-HT1B receptor antagonism. Thus, it might represent a valuable future option in the pulmonary arterial hypertension therapy.
PMID: 32333296 [PubMed - as supplied by publisher]
Source: Pharmacological Reports - Category: Drugs & Pharmacology Authors: Baranowska-Kuczko M, Kozłowska H, Schlicker E, Göthert M, MacLean MR, Kozłowski M, Kloza M, Sadowska O, Malinowska B Tags: Pharmacol Rep Source Type: research
More News: Cancer & Oncology | Carcinoma | Celexa | Citalopram | Drugs & Pharmacology | Hypertension | Study